1170024-19-7 Usage
Uses
Used in Pharmaceutical Chemistry:
7-Bromoimidazo[1,2-a]pyridine-2-carboxylic acid Methyl ester is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique structure and functional groups make it a valuable building block in the development of new therapeutic agents.
Used in Organic Synthesis:
7-Bromoimidazo[1,2-a]pyridine-2-carboxylic acid Methyl ester is used as a key intermediate in the synthesis of complex organic molecules. Its versatile structure allows for further functionalization and modification, making it a useful compound in the field of organic chemistry.
Used in Research and Development:
7-Bromoimidazo[1,2-a]pyridine-2-carboxylic acid Methyl ester is used as a research compound in academic and industrial laboratories. Its properties and reactivity are studied to gain insights into the behavior of imidazopyridine derivatives and their potential applications in various fields.
Check Digit Verification of cas no
The CAS Registry Mumber 1170024-19-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,7,0,0,2 and 4 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1170024-19:
(9*1)+(8*1)+(7*7)+(6*0)+(5*0)+(4*2)+(3*4)+(2*1)+(1*9)=97
97 % 10 = 7
So 1170024-19-7 is a valid CAS Registry Number.
1170024-19-7Relevant articles and documents
3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR
-
Page/Page column 71, (2019/01/16)
The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.